Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently issued reports on LXEO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lexeo Therapeutics in a report on Thursday. Leerink Partners reissued an “outperform” rating and set a $15.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, September 23rd. Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Lexeo Therapeutics in a research report on Tuesday, September 22nd. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average target price of $16.43.

Read Our Latest Research Report on Lexeo Therapeutics

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $2.87 on Friday. The company has a market cap of $235.48 million, a PE ratio of -2.50 and a beta of 1.64. Lexeo Therapeutics has a twelve month low of $2.55 and a twelve month high of $10.99. The company’s 50 day moving average is $3.38 and its two-hundred day moving average is $5.01.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Montanova Capital LLC grew its stake in shares of Lexeo Therapeutics by 410.7% during the 2nd quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock worth $29,718,000 after purchasing an additional 5,134,200 shares during the period. BlackRock Inc. purchased a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at approximately $26,717,000. Affinity Asset Advisors LLC lifted its stake in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock valued at $28,988,000 after purchasing an additional 1,850,211 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in shares of Lexeo Therapeutics by 9.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock valued at $22,459,000 after purchasing an additional 400,000 shares during the period. Finally, Jupiter Topco LLC acquired a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $18,409,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Further Reading

Analyst Recommendations for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.